Last updated: April 30, 2026
Danazol remains an established androgenic steroid used primarily for hereditary angioedema (HAE) prophylaxis and select gynecologic indications (notably endometriosis and fibrocystic breast disease in some markets). Clinical development activity is limited relative to newer modalities; most recent “updates” in the public domain center on ongoing registry follow-ups, pharmacovigilance, and repurposing-focused observation rather than large-scale, new-phase randomized trials. Market dynamics are driven by generic availability, pricing pressure, and guideline positioning of danazol versus modern first-line HAE therapies (C1 inhibitor replacement, kallikrein inhibitors, and monoclonal antibodies).
What is the current clinical trials footprint for danazol?
What do public trial registries show by trial phase (operational summary)
Across major global registries, danazol’s profile skews toward:
- Interventional trials: smaller studies focused on specific patient subsets, comparative symptom outcomes, or historical-condition reassessment rather than definitive contemporary superiority trials.
- Observational studies: drug safety, tolerability, and real-world utilization, often in conditions where danazol remains an option in certain geographies or where older therapeutic pathways are being documented.
In practical terms, there is no evidence in the open registry record of broad, late-stage (Phase 3) danazol programs that would reset market expectations. The clinical narrative is dominated by use-case persistence (particularly HAE) and safety monitoring.
Clinical trial themes that still recur
- Hereditary angioedema prophylaxis
Trials and studies tend to address dosing practicality, effect on attack frequency, and adverse event patterns relative to alternative therapies available in the same era.
- Gynecologic indications
Studies are smaller and more variable by jurisdiction, reflecting shifting standards of care and the market effect of generics.
- Safety and tolerability
Post-marketing and observational follow-up remain the most visible “trial-like” activity, consistent with androgenic adverse event monitoring needs.
Key practical implication
For investment or R&D planning, danazol’s clinical pipeline signal is low-to-modest in intensity and centered on maintenance of evidence, not on launching a new registration path.
How does danazol’s market behave today?
Demand drivers
- HAE prophylaxis option in constrained settings
Danazol is retained where newer therapies are unavailable, reimbursed unevenly, or where a clinician chooses an older oral prophylactic option.
- Generic economics
Broad generic entry compresses unit pricing and reduces incentive for branded differentiation.
- Guideline-dependent utilization
Danazol’s position is sensitive to national guidance and payer reimbursement structures.
Supply-side reality
- Multiple generic manufacturers in most mature markets
Danazol is a mature API, with pricing anchored to generic competition rather than to novel-evidence premiums.
- Manufacturing and formulation remain stable
Most market supply is based on legacy formulations, with formulation innovation not a dominant competitive axis.
Competitive set (relevant substitutes)
Danazol faces substitution on therapeutic pathways, especially in HAE:
- C1 inhibitor therapies (replacement and subcutaneous strategies)
- Kallikrein inhibitors
- Bradykinin pathway monoclonal antibodies
In gynecologic uses, substitution trends toward:
- Hormonal therapies with better tolerability
- Modern endometriosis management strategies
Pricing and reimbursement
Because danazol is off-patent in most jurisdictions, the pricing structure is characterized by:
- low absolute drug cost per course,
- high share dispersion by tendering and reimbursement, and
- infrequent payer pull-through for branded premium claims.
What is the realistic projection for danazol’s market through the forecast horizon?
Market projection framework (what matters)
For a mature, off-patent product like danazol, the projection is shaped by:
- volume stability vs incremental declines driven by guideline shift to newer HAE therapies,
- share competition from generic incumbents, and
- regional reimbursement differentials (some markets continue to use danazol more than others).
Base case: stable-to-declining volume, modest revenue erosion
A typical outcome for danazol in high-income markets is:
- slower than oncology-style decay because HAE prophylaxis can remain a clinician-selected oral option,
- revenue pressure driven by generic pricing and gradual substitution away from danazol in favor of newer, targeted agents.
Scenario view (directional)
| Scenario |
Revenue trajectory |
Volume trajectory |
Key drivers |
| Conservative |
Slight decline |
Stable |
Ongoing generic pricing pressure; slow guideline migration |
| Base case |
Moderate decline |
Mild decline |
Uptake of newer HAE therapies where reimbursed; aging treated population |
| Downside |
Accelerated decline |
Meaningful decline |
Broader payer restriction on androgenic prophylaxis and increased switching |
What would change the projection
For danazol specifically, meaningful upside generally requires one of:
- new evidence support that changes guideline tiering in a way that improves reimbursement access, or
- a new market entry strategy that overcomes competitive generic pricing, or
- a major HAE reimbursement reset in regions where danazol is not currently constrained.
Absent those, danazol’s trajectory stays closer to a “mature generics” pattern than to a growth pattern.
Where does danazol stand in HAE treatment strategy today?
Positioning dynamics
In HAE, clinical decisioning increasingly prioritizes bradykinin pathway-targeted prophylaxis and C1 inhibitor strategies when available. Danazol remains relevant where:
- newer therapies are inaccessible or restricted,
- clinicians prefer an oral prophylactic with known long-term experience,
- patients have historical tolerability and adherence stability.
Clinical risk profile affects persistence
Danazol’s androgenic and endocrine-related adverse effects influence long-term prescribing and may reduce initiation in some settings, supporting a slow substitution trend even when the drug is still used.
Key commercial implications for stakeholders
For generic manufacturers and distributors
- Winning is less about clinical novelty and more about contracting, tender access, and consistent supply.
- The commercial playbook is channel management: hospital formularies, payer contracting, and stable procurement.
For innovators and acquirers
- A danazol-linked “pipeline” thesis should be viewed as portfolio stabilization (legacy therapy evidence) rather than as a growth platform.
- If pursuing an innovation thesis, it tends to require a novel formulation, delivery concept, or differentiated safety approach to justify a market premium. For danazol, that is structurally harder because generic erosion caps willingness-to-pay.
Key Takeaways
- Danazol’s clinical trial signal is limited in intensity and is largely dominated by safety and use-case confirmation rather than new late-stage pivotal programs.
- The market is shaped by generic economics and guideline substitution, especially in HAE, where newer targeted therapies increasingly displace older oral prophylaxis where reimbursed.
- The most likely projection is stable-to-declining revenue, driven by mild volume erosion and persistent price compression.
- Commercial leverage comes from reimbursement access, tendering, and reliable supply, not from new clinical differentiation.
FAQs
1. Is danazol still actively developed in Phase 3 programs?
Open registry signals do not indicate a current, broad Phase 3 program that would reset danazol’s market outlook; activity is more consistent with maintenance studies and observational/safety work.
2. What conditions drive most of danazol’s residual demand?
Hereditary angioedema prophylaxis is the most consistent modern demand driver, with gynecologic uses varying by region and guideline adoption.
3. How much does generic competition affect danazol revenue?
Generic competition drives pricing down and limits branded premium potential, making revenue sensitive to tendering and payer contracting.
4. How do newer HAE therapies change danazol’s market trajectory?
Where newer therapies are reimbursed and adopted, they reduce initiation and switching into danazol, producing a gradual volume decline.
5. What would create upside for danazol?
Upside would most plausibly come from a reimbursement or guideline change that re-expands danazol’s tiering, or from a differentiated formulation/safety strategy that supports premium access.
References (APA)
[1] ClinicalTrials.gov. (n.d.). Search results for danazol. https://clinicaltrials.gov/
[2] European Medicines Agency. (n.d.). Danazol product information and EPAR-related documents where available. https://www.ema.europa.eu/
[3] U.S. National Library of Medicine. (n.d.). Drug database and related records for danazol. https://pubchem.ncbi.nlm.nih.gov/
